

<i>Anaplasma phagocytophilum</i> infection	1	0.03	18	0.12	107	0.27	147	0.35	361	0.57	1,914	1.91	1,596	3.35	7	4,151
<i>Ehrlichia chaffeensis</i> infection	1	0.03	6	0.04	46	0.12	87	0.21	153	0.24	610	0.61	466	0.98	8	1,377
<i>Ehrlichia ewingii</i> infection	–	–	–	–	–	–	–	–	2	0.00	9	0.01	11	0.02	–	22
Undetermined ehrlichiosis/anaplasmosis	–	–	3	0.02	15	0.04	15	0.04	36	0.06	76	0.08	54	0.11	1	200
Giardiasis	104	3.40	1,607	13.06	1,911	6.04	1,880	5.54	3,461	6.76	5,297	6.46	1,991	5.03	59	16,310
Gonorrhea	95	2.39	92	0.58	2,534	6.17	218,302	501.72	192,987	294.86	51,384	49.43	1,599	3.25	1,521	468,514
<i>Haemophilus influenzae</i> , invasive disease																
All ages, all serotypes	351	8.84	221	1.38	128	0.31	120	0.28	315	0.48	1,209	1.16	2,546	5.17	5	4,895
Age <5 years																
Serotype b	19	0.48	11	0.07	–	–	–	–	–	–	–	–	–	–	–	30
Non-b serotype	78	1.96	81	0.51	–	–	–	–	–	–	–	–	–	–	–	159
Nontypeable	137	3.45	59	0.37	–	–	–	–	–	–	–	–	–	–	–	196
Unknown serotype	117	2.95	70	0.44	–	–	–	–	–	–	–	–	–	–	–	187
Hansen's disease	–	–	–	–	3	0.01	4	0.01	7	0.01	29	0.03	18	0.04	17	78
Hantavirus infection, non-hantavirus pulmonary syndrome	–	–	–	–	1	0.00	1	0.00	2	0.00	2	0.00	–	–	–	6
Hantavirus pulmonary syndrome	–	–	–	–	2	0.00	4	0.01	7	0.01	12	0.01	6	0.01	–	31
Hemolytic uremic syndrome post-diarrheal	9	0.23	143	0.92	100	0.25	13	0.03	10	0.02	11	0.01	19	0.04	2	307
Hepatitis §																
A, acute	1	0.03	18	0.11	59	0.14	265	0.61	618	0.94	738	0.71	301	0.61	7	2,007
B, acute	1	0.03	–	–	4	0.01	107	0.25	1,192	1.84	1,705	1.65	198	0.40	11	3,218
B, perinatal infection	17	0.43	15	0.38	–	–	–	–	–	–	–	–	–	–	–	32
C, acute	7	0.19	3	0.02	–	–	531	1.30	1,528	2.47	784	0.80	68	0.15	21	2,942
Human immunodeficiency virus diagnoses	39	0.98	15	0.09	67	0.16	7,243	16.65	15,630	23.88	11,052	10.63	729	1.48	–	34,775
Influenza-associated pediatric mortality	8	0.20	26	0.16	39	0.10	9	0.07	–	–	–	–	–	–	–	82
Invasive pneumococcal disease																
All ages	395	13.42	717	6.05	464	1.52	315	0.97	1,425	2.96	7,305	9.40	6,972	18.68	33	17,626
Confirmed	393	13.35	715	6.04	464	1.52	315	0.97	1,425	2.96	7,299	9.39	6,959	18.64	33	17,603
Probable	2	0.07	2	0.02	–	–	–	–	–	–	6	0.01	13	0.03	–	23
Age <5 years	408	12.86	734	5.75	–	–	–	–	–	–	–	–	–	–	–	1,142
Confirmed	406	12.80	731	5.72	–	–	–	–	–	–	–	–	–	–	–	1,137
Probable	2	0.06	3	0.02	–	–	–	–	–	–	–	–	–	–	–	5
Legionellosis	3	0.08	2	0.01	4	0.01	61	0.14	398	0.61	2,927	2.82	2,742	5.57	4	6,141
Leptospirosis	–	–	–	–	3	0.01	11	0.03	17	0.03	36	0.05	11	0.03	–	78
Listeriosis	34	0.86	1	0.01	5	0.01	20	0.05	61	0.09	183	0.18	480	0.97	2	786
Lyme disease																
Total	21	0.53	1,283	8.08	5,776	14.13	3,495	8.07	4,822	7.40	12,970	12.53	7,360	15.02	702	36,429
Confirmed	20	0.51	1,074	6.76	4,472	10.94	2,343	5.41	3,311	5.08	9,355	9.04	5,045	10.30	583	26,203
Probable	1	0.03	209	1.32	1,304	3.19	1,152	2.66	1,511	2.32	3,615	3.49	2,315	4.72	119	10,226
Malaria	8	0.20	91	0.57	194	0.47	258	0.59	568	0.87	702	0.68	132	0.27	2	1,955
Measles																
Total	5	0.13	9	0.06	14	0.03	16	0.04	26	0.04	15	0.01	–	–	–	85
Indigenous	4	0.10	7	0.04	8	0.02	15	0.03	21	0.03	13	0.01	–	–	–	68
Imported	1	0.03	2	0.01	6	0.01	1	0.00	5	0.01	2	0.00	–	–	–	17
Meningococcal disease																
All serogroups	35	0.88	33	0.21	21	0.05	80	0.18	64	0.10	80	0.08	62	0.13	–	375
Serogroups ACWY	5	0.13	16	0.10	6	0.01	14	0.03	16	0.02	39	0.04	30	0.06	–	126
Serogroup B	18	0.45	10	0.06	6	0.01	25	0.06	11	0.02	8	0.01	8	0.02	–	86
Other serogroups	1	0.03	2	0.01	1	0.00	6	0.01	5	0.01	4	0.00	2	0.00	–	21
Unknown serogroup	11	0.28	5	0.03	8	0.02	35	0.08	32	0.05	29	0.03	22	0.04	–	142
Mumps	16	0.40	192	1.20	1,623	3.95	2,716	6.24	1,125	1.72	626	0.60	62	0.13	9	6,369
Novel Influenza A virus infections	1	0.03	6	0.04	9	0.02	2	0.00	–	–	4	0.00	–	–	1	23
Pertussis	2,020	50.88	2,435	15.26	5,833	14.21	3,998	9.19	1,094	1.67	1,905	1.83	657	1.33	30	17,972
Plague	–	–	–	–	–	–	2	0.00	–	–	–	–	2	0.00	–	4
Polioomyelitis, paralytic	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Poliovirus infection, nonparalytic	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Psittacosis	–	–	–	–	–	–	2	0.01	3	0.01	5	0.01	2	0.00	–	12

Q fever																
Total	—	—	1	0.01	2	0.00	6	0.01	25	0.04	89	0.09	41	0.08	—	164
Acute	—	—	1	0.01	2	0.00	5	0.01	21	0.03	72	0.07	31	0.06	—	132
Chronic	—	—	—	—	—	—	1	0.00	4	0.01	17	0.02	10	0.02	—	32
Rabies																
Human	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Rubella	—	—	—	—	—	—	—	—	1	0.00	—	—	—	—	—	1
Rubella, congenital syndrome	2	0.05	—	—	—	—	—	—	—	—	—	—	—	—	—	2
Salmonellosis	5,126	129.11	7,321	45.88	5,724	13.94	4,989	11.47	7,687	11.74	13,917	13.39	8,562	17.39	524	53,850
Severe acute respiratory syndrome-associated coronavirus disease	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Shiga toxin-producing <i>Escherichia coli</i> †	340	8.56	1,782	11.17	1,400	3.41	1,320	3.03	1,275	1.95	1,159	1.12	806	1.64	87	8,169
Shigellosis	289	7.28	5,181	32.47	6,035	14.70	1,642	3.77	3,722	5.69	3,144	3.02	984	2.00	100	21,097
Smallpox	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Spotted fever rickettsiosis																
Total	2	0.05	45	0.28	186	0.46	353	0.82	823	1.27	1,924	1.86	931	1.90	5	4,269
Confirmed	—	—	2	0.01	14	0.03	13	0.03	23	0.04	67	0.06	35	0.07	—	154
Probable	2	0.05	43	0.27	172	0.42	340	0.79	800	1.23	1,857	1.80	896	1.83	5	4,115
Streptococcal toxic shock syndrome	1	0.04	4	0.04	18	0.07	9	0.03	43	0.10	123	0.18	85	0.26	—	283
Syphilis																
Total, all stages **	634	15.97	4	0.03	42	0.10	17,544	40.32	41,556	63.49	26,306	25.31	1,867	3.79	89	88,042
Congenital	628	15.82	—	—	—	—	—	—	—	—	—	—	—	—	—	628
Primary and secondary	—	—	2	0.01	17	0.04	6,470	14.87	13,498	20.62	7,511	7.23	279	0.57	37	27,814
Tetanus	—	—	—	—	5	0.01	2	0.00	9	0.01	6	0.01	3	0.01	9	34
Toxic shock syndrome (other than Streptococcal)	—	—	—	—	15	0.05	17	0.06	3	0.01	5	0.01	—	—	—	40
Trichinellosis	—	—	—	—	2	0.01	2	0.00	4	0.01	14	0.01	4	0.01	—	26
Tuberculosis	48	1.21	176	1.10	163	0.40	938	2.16	2,206	3.37	3,470	3.34	2,264	4.60	7	9,272
Tularemia	1	0.03	14	0.09	19	0.05	17	0.04	29	0.04	99	0.10	51	0.10	—	230
Typhoid fever	2	0.05	32	0.20	79	0.19	78	0.18	111	0.17	60	0.06	7	0.01	7	376
Vancomycin-intermediate <i>Staphylococcus aureus</i>	1	0.03	1	0.01	2	0.01	4	0.01	15	0.03	48	0.06	37	0.10	—	108
Vancomycin-resistant <i>Staphylococcus aureus</i>	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Varicella morbidity	768	23.90	1,927	14.95	3,228	9.75	912	2.60	822	1.55	577	0.69	112	0.29	607	8,953
Varicella mortality	U	U	U	U	U	U	U	U	U	U	U	U	U	U	U	U
Vibriosis																
Total	3	0.08	25	0.16	121	0.30	93	0.22	194	0.30	495	0.48	335	0.69	7	1,273
Confirmed	2	0.05	23	0.15	120	0.30	93	0.22	184	0.29	491	0.48	325	0.67	3	1,241
Probable	1	0.03	2	0.01	1	0.00	—	—	10	0.02	4	0.00	10	0.02	4	32
Viral hemorrhagic fevers																
Crimean-Congo hemorrhagic fever virus	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Ebola virus	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Guanarito virus	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Junin virus	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Lassa virus	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Lujo virus	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Machupo virus	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Marburg virus	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Sabia virus	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Yellow fever	—	—	—	—	—	—	—	—	—	—	—	—	1	0.00	—	1
Zika virus																
Zika virus disease, congenital ††	25	0.63	—	—	—	—	—	—	—	—	—	—	—	—	5	30
Zika virus disease, non-congenital	3	0.08	22	0.14	180	0.44	764	1.76	1,810	2.77	2,077	2.00	272	0.55	4	5,132
Zika virus infection, congenital ††	29	0.73	—	—	—	—	—	—	—	—	—	—	—	—	16	45
Zika virus infection, non-congenital	1	0.03	—	—	6	0.01	295	0.68	545	0.83	51	0.05	12	0.02	1	911

—: No reported cases U: Unavailable

* Reportable in <25 states.

† Total number of reported laboratory-positive dengue cases, including all confirmed cases [by anti-dengue virus (DENV) molecular diagnostic methods or seroconversion of anti-DENV IgM] and all probable cases (by a single, positive anti-DENV IgM).

§ Chronic hepatitis B and C data are not included in NNDSS tables but reported case counts are included in the annual Summary of Viral Hepatitis, published online by CDC's

Division of Viral Hepatitis, available at <https://www.cdc.gov/hepatitis/statistics/2015surveillance/index.htm>.

¶ Includes *Escherichia coli* O157:H7; shiga toxin-positive, serogroup non-O157; and shiga toxin positive, not serogrouped.

** Includes syphilis of all stages, including cases where stage of syphilis is not stated.

†† Data reported to ArboNET using the national surveillance case definition for congenital Zika virus disease or infection (CSTE Position Statement 16-ID-01). Additional data reported to the US Zika Pregnancy Registry for outcomes of pregnancies with laboratory evidence of possible Zika virus infection are available at <https://www.cdc.gov/zika/reporting/pregnancy-outcomes.html>. Cases reported to the US Zika Pregnancy Registry might not meet the national surveillance case definition for congenital Zika virus disease or infection.

Notes:

- These are **annual** cases of selected infectious national notifiable diseases from the National Notifiable Diseases Surveillance System (NNDSS). NNDSS data reported by the 50 states, New York City, the District of Columbia, and the U.S. territories are collated and published. Cases are reported by state health departments to CDC weekly. Annual data may differ from previously reported weekly and quarterly data due to revision of information and delayed reporting.
- The list of national notifiable infectious diseases and conditions for 2016 and their national surveillance case definitions are available at <https://www.cdc.gov/nndss/conditions/notifiable/2016/infectious-diseases/>. This list incorporates the Council of State and Territorial Epidemiologists (CSTE) position statements approved in 2015 by CSTE for national surveillance, that were implemented in January 2016, including updated surveillance case definitions for acute hepatitis C and chronic hepatitis C virus infections. 2016 data are reported through June 30, 2017. Publication criteria for the finalized 2016 data are available at /nndss/documents/2016_NNDSS_Publication_Criteria.pdf. See also [Guide to Interpreting Provisional and Finalized NNDSS Data](#).
- Population estimates for incidence rates are July 1st, 2016 estimates obtained from the National Center for Health Statistics (NCHS) postcensal estimates of the resident population of the United States for July 1, 2011 - July 1, 2016, by year, county, single year of age (range: 0 to 85 years), bridged-race (white, black or African American, American Indian or Alaska Native, Asian, or Pacific Islander), Hispanic ethnicity (not Hispanic or Latino, Hispanic or Latino), and sex (Vintage 2016), prepared under a collaborative arrangement with the U.S. Census Bureau. Population estimates for states as of June 26, 2017 are available at https://www.cdc.gov/nchs/nvss/bridged_race/data_documentation.htm. Population estimates for territories are the 2016 mid-year estimates from the U.S. Census Bureau International Data Base accessed on July 24, 2017 at <https://www.census.gov/population/international/data/idb/informationGateway.php>. The choice of population denominators for incidence is based on the availability of population data at the time of publication preparation.
- NNDSS data displayed in the annual tables are accurate as of October 17, 2017; source data may be updated as additional information is received.
- Annual tables for 2016 are available on [CDC WONDER](#).
- Annual summary reports from 1993-2015 are available as published in the [MMWR](#).
- Annual summary reports from 1952-1992 are available as published in the [MMWR](#) in the [CDC Stacks](#).

[National Notifiable Diseases Surveillance System](#)

Provided by [CDC WONDER](#)